Immutep Limited (IMMP) is a Sydney-based, clinical-stage biotechnology company pioneering therapies built around LAG-3, an immune checkpoint it both stimulates to fight cancer and suppresses to calm autoimmune disease. Its lead cancer asset is eftilagimod alfa ("efti"), while IMP761 is a first-in-class LAG-3 agonist antibody in early autoimmune testing. On Thursday morning, the stock traded at $3.38, up $0.13 or 4.00%, from the previous session's close of $3.25, confirming an upward move. The immediate trigger was the release of new EFTISARC-NEO survival and biomarker analyses presented at the Connective Tissue Oncology Society annual meeting, layered on top of a strategy update issued a day earlier.
The headline release of the session expanded on an abstract first published on 11 November. In the investigator-initiated Phase II study of efti combined with Keytruda and radiotherapy before surgery in high-risk, resectable soft tissue sarcoma, 38 of 40 enrolled patients underwent surgery and were evaluable. Twelve-month disease-free survival was 81.1%, with an 18-month estimate holding at 81.1% on immature data, alongside 94.1% local recurrence-free survival and 86.2% distant metastasis-free survival after a median 19.1 months of follow-up.
What drove the market reaction was the exploratory analysis. Patients whose post-treatment tumour-infiltrating lymphocyte levels exceeded 310 cells/mm² recorded 95.0% 12-month disease-free survival versus 64.9% for those below that threshold, and patients with treatment-related hyalinisation and fibrosis above 52% recorded 93.8% versus 71.4%. That link between measurable immune activation in the tumour and better outcomes reinforces the case that efti is doing what its mechanism of action predicts — the central argument for a program that has had little to celebrate in 2026. The company said it is preparing a registration-directed trial in neoadjuvant sarcoma targeting a second-half 2027 start, subject to regulatory feedback, manufacturing and partnering.
The move also extended a two-week recovery from the year's lows near $2.69. That rebound began with the reset narrative laid out in the 18 November investor update, in which Immutep disclosed that its root cause analysis of the failed Phase III TACTI-004 lung cancer trial had found subtle differences in glycan structures between efti manufactured at 2,000-litre scale and the 200-litre material used in earlier studies. All batches met release specifications, but the differing immune-monitoring profile gave management a coherent explanation for the futility outcome. The company has contracted a new 200-litre batch and narrowed its focus to head and neck squamous cell carcinoma with CPS below 1 and neoadjuvant sarcoma, both backed by FDA designations. The same window brought positive Phase I IMP761 data at ACR Convergence and a fifth U.S. patent covering efti-based combinations.
Turnover has averaged roughly 15,000 shares a session over the past three months, with the heaviest volumes clustered on 6 November, 9 November and 18 November, when daily gains of 24.2%, 13.8% and 2.2% respectively attracted fresh attention. Activity in the opening minutes on Thursday was modest, consistent with a small, retail- and event-driven shareholder base rather than an institutional re-rating. The advance was idiosyncratic: it followed a company-specific scientific release, and no corresponding industry-wide or macro catalyst was evident. Technically, the stock is pressing back toward the $3.50–$3.66 band that capped the November rebound, having bottomed near $2.69 on 5 November; the broader sequence since September remains a deep downtrend from above $7.50.
The score runs from 0 to 100, where 0 means no meaningful news and a move normal for the stock, and 100 means transformative news paired with an extreme, rare price move. IMMP earns 23 out of 100.
The verified news was moderate in weight: the 81.1% survival figure had already been disclosed on 11 November, so Thursday's increment was biomarker detail and trial-pathway clarity on a secondary endpoint of a 40-patient study — meaningful for sentiment, not decisive for valuation. The price move was equally unremarkable: at 4.00% it was essentially identical to the stock's average absolute daily move of about 4.0% over the last 60 sessions, and 21 of those sessions produced moves of equal or greater size. Weak news and a routine swing combine into a low score.
The near-term calendar is dense. Immutep holds its annual general meeting on 27 November, where it has said it will present the outcome of the TACTI-004 root cause analysis — the single largest outstanding question for investors. Final overall survival data from the head and neck cancer program is expected at ESMO Immuno-Oncology in December, and multiple ascending dose results for IMP761 are guided for the first half of 2027. Analyst coverage remains constructive but sparse, with a Moderate Buy consensus and wide dispersion in published targets. The principal risks are familiar for a micro-cap developer: a high chance that the root cause analysis proves inconclusive, manufacturing and regulatory delays pushing the sarcoma trial beyond 2027, the need to partner or raise capital before the guided runway into the first half of 2028 is exhausted, and the low liquidity that can exaggerate moves in either direction.
Tickeron maintains hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are highlighted in the curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the list offers a practical starting point for matching a system to your own approach. Reviewing the current leaders is a simple way to see which strategies are working in this tape.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
The RSI Oscillator for IMMP moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 23 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IMMP as a result. In 65 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for IMMP just turned positive on October 20, 2026. Looking at past instances where IMMP's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.
Following a +7.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMMP advanced for three days, in 208 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 45 cases where IMMP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMMP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
IMMP broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for IMMP entered a downward trend on November 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating steady price growth. IMMP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.999) is normal, around the industry mean (3.596). P/E Ratio (-0.310) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (443.347).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMMP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of anti-cancer therapeutics
Industry Biotechnology